Standout Papers

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherap... 2009 2026 2014 2020 550
  1. Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma (2009)
    Richard Piekarz, Robin Frye et al. Journal of Clinical Oncology

Immediate Impact

4 by Nobel laureates 9 from Science/Nature 65 standout
Sub-graph 1 of 21

Citing Papers

Transient loss of Polycomb components induces an epigenetic cancer fate
2024 StandoutNature
Expanding chemistry through in vitro and in vivo biocatalysis
2024 StandoutNature
11 intermediate papers

Works of Robin Frye being referenced

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
2010
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
and 5 more

Author Peers

Author Last Decade Papers Cites
Robin Frye 1066 430 356 467 19 1.6k
Poul Knoblauch 716 390 277 515 17 1.2k
Patrick A. Oberholzer 878 325 245 764 26 1.8k
Sarah M. Kehoe 1068 401 71 790 12 2.0k
Danny F. Dukers 597 637 201 738 30 1.6k
Alka Palekar 602 786 287 555 31 1.8k
E B Bröcker 653 266 99 443 27 1.4k
Keld Kaltoft 472 242 322 604 30 1.6k
Christian S. R. Hatton 1690 279 66 191 14 2.1k
Lise Boussemart 824 125 101 707 17 1.6k
Kyri Dunussi‐Joannopoulos 238 219 436 303 19 2.0k

All Works

Loading papers...

Rankless by CCL
2026